Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2023-12-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Document" or "Sponsorship Letter" related to a specific stock issuance by 盈康生命科技股份有限公司 (INKON Life Technology Co., Ltd.). It details the issuance of shares to specific investors, including information about the issuer, financial data, risk factors, issuance details, pricing, and regulatory compliance. The document is issued by 国泰君安证券股份有限公司 as the sponsor for the issuance. This type of document is typically a formal underwriting or sponsorship document related to a capital raising event, specifically a private placement or directed share issuance to specific investors. It is not a general annual report, earnings release, or management report. It is not a proxy, voting result, or governance document. It is not a transcript or legal proceeding report. It is a detailed capital/financing update related to a specific share issuance event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed financial data support that this is a substantive report, not just an announcement or certification, so it is not RPA or RNS.
2023-12-29 Chinese
关于2022年向特定对象发行股票预案及相关文件二次修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of a 2022 plan for a specific share issuance to targeted investors by 盈康生命科技股份有限公司. It details updates to the issuance plan, analysis reports, feasibility reports, and risk disclosures related to the share issuance. The content focuses on the company's capital raising activities, including changes in the number of shares to be issued, fundraising amounts, and related approvals. There is no indication that this is the full issuance plan itself but rather an announcement of revisions and updates to the issuance plan and related documents. The document length is 3152 characters, which is relatively short and consistent with an announcement rather than a full detailed report. Therefore, this fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2023-12-29 Chinese
2022年向特定对象发行股票方案论证分析报告（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 年向特定对象发行股票方案论证分析报告（二次修订稿）" which translates to "2022 Non-public Offering of Shares Proposal Analysis Report (Second Revised Draft)". The content extensively discusses the background, purpose, legal compliance, pricing, and fairness of a specific share issuance to designated investors. It includes detailed financial impact analysis, regulatory references, and procedural compliance related to a capital raising event through a targeted stock issuance. There is no indication that this is a general annual report, earnings release, or management discussion. Instead, it is a detailed report analyzing and justifying a capital/financing activity, specifically a non-public share issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to the explicit focus on share issuance scheme and financing details.
2023-12-29 Chinese
第六届董事会第五次（临时）会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a specific board meeting (the sixth board's fifth interim meeting) of the company 盈康生命科技股份有限公司. It discusses adjustments to a specific capital raising plan involving issuance of shares to a particular investor, including voting results, pricing, quantity, and related agreements. The content focuses on board decisions regarding a capital increase and related shareholder approvals, with no financial statements or earnings data presented. The document is not a full financial report, earnings release, or audit report. It is not a proxy statement or AGM materials but rather a formal announcement of board resolutions related to a capital financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (6101 characters) and detailed content support this classification with high confidence.
2023-12-29 Chinese
盈康生命科技股份有限公司2022年度向特定对象发行股票募集说明书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" (Prospectus) for a "2022年度向特定对象发行股票" (2022 private placement of shares) by 盈康生命科技股份有限公司 (Inkon Life Technology Co., Ltd.). It contains detailed information about the issuance of shares to a specific investor, including pricing, number of shares, use of proceeds, risk factors, legal and regulatory compliance, and statements from company directors and auditors. The document is comprehensive and lengthy (15,000 characters), indicating it is the actual offering prospectus rather than a brief announcement. The content focuses on capital raising activities, share issuance details, and related disclosures. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an Annual Report, Earnings Release, or other categories. Therefore, the correct classification is CAP with high confidence.
2023-12-29 Chinese
关于向特定对象发行股票摊薄即期回报的风险提示及采取填补措施和相关主体承诺（二次修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a company's plan to issue new shares to specific investors, including risk warnings about dilution of immediate returns, financial impact analysis, measures to mitigate dilution risks, and commitments from controlling shareholders and management. It references regulatory guidelines and includes financial projections and governance measures related to the issuance. The content focuses on capital raising and its effects on financial metrics, which aligns with updates on financing activities or capital structure changes. The document is not a full financial report, audit, or earnings release, nor is it a simple announcement of a report publication. It is a comprehensive disclosure about a capital raising event and related risk disclosures. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.